ArticleFuture oncology (London, England)2024

Real-world comparative effectiveness and safety of pembrolizumab for PD-L1≥50% metastatic non-small-cell lung cancer.

Ambica Parmar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.